Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04590326
Title Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Age Groups: adult | senior
Covered Countries USA | BEL

No variant requirements are available.